Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm moxetumomab pasudotox in relapsed or refractory pediatric B-cell ALL or B-cell lymphoblastic lymphoma
NL-OMON41557Phase 2Not yet recruiting
- Sponsor
- MedImmune
- Start
- Oct 2014
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of moxetumomab pasudotox in acute lymphoblastic leukemia (ALL) and precursor B-lymphoblastic lymphoma (B-LBL), sponsored by MedImmune. Primary endpoint: Composite complete response rate. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
moxetumomab pasudotox
03
Conditions
acute lymphoblastic leukemia (ALL)precursor B-lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NL-OMON41557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41557.